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The DNA mismatch repair (MMR) pathway is a very important DNA repair pathway to
maintain genomic integrity. Germline mutations in the MMR genes can cause a
hereditary cancer predisposition syndrome, Lynch Syndrome (LS). LS patients develop
colorectal cancer as well as other extracolonic cancers at an early age. However, how
the loss of DNA MMR leads to tumorigenesis remains unclear. The MMR mediated
DNA damage response to the alkylating agent N-methyl-N’-nitro-N-nitrosoguanidine
(MNNG) observed in various cancer cell lines may contribute to preventing
tumorigenesis by eliminating damaged cells. In the first part of this study, we examined
the MMR dependent DNA damage response in the human pluripotent stem cell (hPSC)
which is a nontransformed cell model. We found that hPSCs are hypersensitive to
alkylation damage which triggers massive apoptosis. Interestingly, the nature of this
alkylation response differs from that previously reported in somatic cells. In somatic
cells, a permanent G2/M cell cycle arrest is induced in the second cell cycle after DNA
damage. The hPSCs, however, directly undergo apoptosis in the first cell cycle.
Furthermore, the signaling mechanisms of this damage response are also very different
from somatic cells in that the checkpoint kinases Chk1 and Chk2 are not activated in
hPSCs in response to alkylation damage, but rather p53 activation is responsible for
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inducing apoptosis. This response reveals that hPSCs rely on apoptotic cell death as an
important defense to avoid mutation accumulation.
Since LS patients predominantly develop colorectal cancer and human embryonic
stem cells (hESCs) can be differentiated into intestinal organoids in vitro, in the second
part of this study we generated both hESCs-derived human intestinal organoids (HIOs)
and adult human intestinal enteroids (HIEs) from patient colon samples to study the
damage responses to alkylation damage in intestinal cells specifically. We found that
the MMR pathway can direct multiple responses to DNA damage in different intestinal
cell types in HIOs. Intestinal stem cells (ISCs) appear more prone to undergo apoptosis
in response to DNA damage whereas more differentiated cells such as the transient
amplifying cells are more likely to senesce. Both mechanisms may play an important
role in tumor suppression by eliminating or halting progression of damaged cells.
Therefore loss of MMR pathway function might provide an immediate selective
advantage at an early stage during tumorigenesis in LS patients. Taken together, this
work further reveals the MMR-dependent DNA damage response in nontransformed cell
types and cell types related to LS, and provides insights into how loss of these damage
responses may contribute to tumorigenesis at an early stage in LS patients.
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CHAPTER 1
Introduction

A. Lynch Syndrome

Lynch Syndrome (LS) is a hereditary cancer syndrome that predisposes patients to
colorectal cancer as well as other extracolonic cancers including endometrial cancer,
ovarian cancer, gastric cancer etc. It is the most common form of hereditary colon
cancer, accounting for approximately 2-7% of all colorectal cancers. These cancers are
typically early onset, rapidly progressing and resistant to many chemotherapeutic
agents. Lynch syndrome is caused by mutations in DNA mismatch repair (MMR) genes
(MSH2, MSH6, MLH1, PMS2) and inherited in an autosomal dominant fashion. An
individual inherits one defective allele and losses the remaining wild type copy
sporadically later during their lifetime (Poulogiannis et al., 2010; Lynch et al., 2015). The
diagnosis is now based on genetic testing of MMR genes. The revised Amsterdam
criteria II guidelines have been used clinically to identify high-risk candidates for genetic
testing and rely heavily on family history (Table 1-1) (Vasen et al., 2007). Due to
limitations of the Amsterdam criteria, many patients were likely missed so now many
medical centers perform molecular testing on all colorectal cancer (CRC) patients,
including test for microsatellite instability which is a hallmark of MMR deficiency and
immunohistochemistry for MMR proteins prior to sequencing for MMR mutations.
Identified carriers of MMR mutations are advised to undergo early and frequent cancer
screenings as well as preventive surgeries. Once a tumor is detected, the first line
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Table 1-1 Amsterdam Criteria II for Lynch syndrome
1. Three or more relatives with an LS-associated cancer (colorectal cancer, endometrial
cancer, cancer of the small bowel, ureter or renal pelvis), one of whom is a first-degree
relative of the other two.
2. At least two successive generations affected
3. At least one case diagnosed before age 50
4. Familial adenomatous polyposis excluded
5. Tumors verified by pathologic examination
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therapy is surgery and chemotherapy. However, LS tumors are naturally resistant to the
commonly used chemotherapeutic agent for colorectal cancer 5-fluorouracil (5-FU) due
to MMR deficiency, highlighting the need for novel therapeutics for LS patients (Tajima
et al., 2004).

B. Mismatch repair

DNA MMR is a highly conserved cellular process throughout evolution and is essential
for maintaining genomic integrity. MMR can recognize and repair base mismatches and
small insertion/deletion loops (IDLs) that arise in DNA primarily due to polymerase
misincorporation errors, but also through cellular and exogenous DNA damaging agents
(Jiricny, 2006) (Li, 2008). The mechanism of MMR has been extensively studied in
Escherichia coli and repairby the bacterial system has been reconstituted in vitro. This
purified system relies on the activities of the MMR proteins MutS, MutL, and MutH, as
well as DNA helicase II, exonuclease I, single-strand binding protein (SSBP), DNA
polymerase III, and DNA ligase (Lahue et al., 1989). The MMR system is evolutionarily
conserved from bacteria to humans, though MMR in the eukaryotic system is more
complex. Several MutS and MutL homologs have been identified in the yeast and
mammalian systems (Fishel and Wilson,1997). MutS homologs MSH2, MSH3, and
MSH6 form two heterodimeric complexes with specific yet partially redundant DNA
lesion recognition activities. MSH2-MSH6 recognizes single base-base mismatches and
small IDL loops in DNA, while MSH2-MSH3 primarily recognizes larger IDL loops.
MSH2-MSH6 signals for repair though a heterodimer of MutL homologs MLH1-PMS2. In
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addition to the activities of MSH2-MSH6 and MLH1-PMS2, this system requires
exonuclease I, the SSBP RPA, polymerase δ, proliferating cell nuclear antigen (PCNA),
the clamp loader RFC, and DNA ligase I (Constantin et al., 2005; Zhang et al., 2005).
Briefly, a single basepair mismatch can be recognized by MSH2-MSH6, which will then
recruit MLH1-PMS2 and exonuclease I leading to the excision of the erroneous strand.
Finally, the resulting single stranded gap is filled in by polymerase resynthesis and
ligated by DNA ligase I (Figure 1-1) (Martin and Scharff, 2002). In vitro experiments
reveal that the excision requires that the heteroduplex substrate contains a pre-existing
nick on the mismatch-containing strand as an entry site for exonuclease I and serves as
a discrimination signal to distinguish the strand to be removed from the template. In vivo,
this discrimination signal could come from gaps between Okazaki fragments in the
lagging strand or the 3' terminus of the newly synthesized leading strand. How MLH1PMS2 is able to detect these structural signals when they may be hundreds of bases
away from the mismatch is unclear (Jiricny, 2006).

Loss of MMR gives rise to an elevated mutation rate, termed the mutator phenotype, as
uncorrected DNA errors become permanent mutations during a subsequent round of
DNA replication (Loeb et at., 1974). In MMR defective cells, the mutator phenotype
manifests in a type of genomic instability called microsatellite instability (MSI).
Mononucleotide, dinucleotide, and larger repeats in the genome are prone to template
slipping during replication due to transient fluctuations in primer annealing. The resulting
looped out bases are normally repaired by the DNA MMR system but become
permanent insertions or deletions when MMR is not functioning. Thus, defective MMR is
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Figure 1-1.
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Figure 1-1.Mechanism of mismatch repair.
The MSH2–MSH6 heterodimer binds to single base-pair mismatches, which then
recruits MLH1-PMS2 as well as the Exo1 exonuclease to the DNA. PCNA which links
the DNA polymerase to the DNA template during replication, also interacts with this
complex, indicating that MMR might be closely associated with the DNA replication fork
(Harfe and Jinks-Robertson, 2000). Single-stranded DNA breaks occur during MMR,
although it is unclear whether they are already present at the replication fork or caused
by the endonuclease activity of MLH1-PMS2 or both. The mismatch-containing strand is
excised by exonuclease Exo1 and then filled-in by DNA polymerase and ligated by DNA
ligase I.

6

not thought to lead to a direct growth advantage as with classic tumor suppressor genes,
but rather, due to the resultant mutator phenotype, it increases the likelihood that other
tumor suppressor genes and oncogenes will become mutated. Several critical genes
involved in cell growth and cell survival (for example TGFβRII, β-catenin, and BAX) are
mutated more often in MMR deficient cells than in normal cells (Duval and Hamelin,
2002).

Besides the protection of genome stability, another MMR function maybe be involved in
preventing tumorigenesis. We propose that the MMR-dependent DNA damage
response may directly affect cell survival. The MMR pathway plays a vital role in the
induction of cell cycle arrest and apoptosis in response to certain forms of DNA damage.
The MSH2-MSH6heterodimer can recognize and bind to an array of lesions including
the G/T mismatch, O6methyl-G/C, O6methyl-G/T, cisplatin adducts, and fluorinated
pyrimidine lesions in DNA generated by 5-FU (Duckett et al., 1996; Hsieh and Yamane,
2008). Interestingly, MMR-deficiency confers tolerance to many DNA damaging agents
that cause these DNA adducts (Stojic et al., 2004a). MMR-proficient human cell lines
were demonstrated to be 100-fold more sensitive to alkylation damage than MMR
deficient cells (Karran, 2001).The most well studied alkylating agent in relation to MMR
mediated DNA damage response is MNNG, which acts as an Sn1 donor and targets the
O6position of guanine to produce the cytotoxic O6-meG lesion (Gerson, 2004). The cell
utilizes methylguanine methyltransferase (MGMT) to remove the methyl group in a
reaction that inactivates MGMT but restores the unmodified guanine. However, if
allowed to persist during DNA replication, the O6-meG can be mispaired with thymidine
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to form O6-meG /T mismatches, which ultimately results in G/C to A/T transitions (Gerson,
2004). The O6-meG /T lesions areefficiently recognized by the MSH2-MSH6 heterodimer
(Duckett et al., 1996). Importantly, MGMT is down-regulated in a variety of cancers
which may lead to an increase in O6-meG lesions (Gerson, 2004). In the laboratory
MGMT can be inhibited by O6-benzylgunanine, which acts as a pseudo-substrate for the
repair protein. Much of the work done to elucidate the MMR-dependent response to
alkylation damage has been performed using cancer cell lines, and treatment of a
MMR-proficient cancer cell line with MNNG results in activation of the DNA damage
response including a permanent G2 cell cycle arrest and apoptosis through activation of
ATM/ATR and downstream cell cycle checkpoint kinases Chk1 and Chk2 in a MMR
dependent-manner (Hickman and Samson, 2004; Stojic et al., 2004b; Mastrocola and
Heinen, 2010a). Interestingly, activation of the G2 cell cycle arrest requires two rounds
of DNA replication (Stojic et al., 2004b).

Two models that are not mutually exclusive have been proposed to account for the role
of MMR in this DNA damage response. The "futile cycle" model proposes that O6-meG/T
mismatches formed during the first round of DNA replication will trigger repeated rounds
of MMR-provoked excision and resynthesis due to the inability of the pathway to repair
the modified base in the parent strand. This process will generate stretches of singlestrand DNA that will be converted into cytotoxic double-strand DNA breaks if left to
persist into the second round of DNA replication (Figure 1-2) (Goldmacher et al., 1986;
York and Modrich, 2006). Alternatively, the direct signaling model proposes that the
MMR machinery directly recruits DNA checkpoint signaling proteins like ATR andChk1
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to the sites of the DNA lesion to initiate and propagate the signal (Figure 1-2) (Lin et al.,
2004; Yang et al., 2004). Since the mechanism of the MMR-dependent DNA damage
response was mainly studied using transformed cell lines, we wished to further study
this damage response in a nontransformed human cell model. Thus, in this study we
investigated the MMR-dependent damage response to MNNG in human pluripotent
stem cells and human intestinal organoids.

C. Human pluripotent stem cells

Human pluripotent stem cells (hPSCs) include human embryonic stem cells (hESCs)
and induced pluripotent stem cells (iPSCs). They are able to differentiate to all three
germ layers and give rise to all the different somatic cell lineages. They can replicate
indefinitely in culture as nontransformed cells. These features make PSCs a good cell
model for us to study the MMR-dependent DNA damage response in normal human
cells. hPSCs are also unique in that they have enhanced DNA repair activities to strictly
maintain genome stability to protect the developing embryo from the damaging effects
of mutations. Many studies have shown that hPSCs are highly efficient at removing
DNA damage compared to somatic cells (Adams et al., 2010; Fung and Weinstock,
2011; Luo et al., 2012; Maynard et al., 2008). DNA damage caused by gammairradiation, ultra-violet irradiation, H2O2 or cross-linking agents are repaired more rapidly
in hESCs than in primary human fibroblasts (Maynard et al., 2008). However, hPSCs
also have very low tolerance for unrepaired DNA damage and react by a robust damage
response leading to apoptosis (Momcilovic et al., 2010; Luo et al., 2012). In Chapter 2
of this study, we examined the activity of the MMR pathway in hPSCs. We particularly
9

Figure 1-2.
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Figure 1-2. Proposed models for activation of the MMR-dependent DNA damage
response.
In both models activation of the DNA checkpoint response requires the initial recognition
of the DNA lesion (in this case an O6-meG/T mismatch). The futile cycle model (upper)
suggests that recognition by the MSH2-MSH6 heterodimer triggers downstream MMR
events including excision; however, since the lesion is in the template strand,
resynthesis will yield an unrepaired lesion. Subsequent rounds of mismatch-provoked
excision and resynthesis, the "futile" cycle", will lead to the generation of a doublestrand break and the activation of the DNA checkpoint response. In the direct signaling
model (lower), DNA associated MSH2-MSH6/MLH1-PMS2 protein complexes act as
damage sensors and directly recruit factors involved in the DNA checkpoint activation.

11

investigated whether hPSCs are capable of eliciting the MMR-dependent damage
response to alkylation damage as observed in human cancer cell lines and other
somatic cell types.

D. Intestinal organoids

In recent years, a series of protocols have been developed to culture human intestinal
cells in three dimensional organoids. Organoids are stem cell-derived human epithelial
"mini-organs". Human intestinal organoids (HIOs) have been created from intact
intestinal crypts as well as through the directed differentiation of hESCs (Cao et al.,
2011; Sato et al., 2011; Spence et al., 2011). Intestinal epithelium consists of millions of
crypts and within each crypt there is a hierarchy of different cell types. A typical colonic
crypt has the intestinal stem cells (ISCs) (marked by Lgr5) at the bottom of the crypt,
which are essential for rapid turnover of the epithelium, transient amplifying (TA) cells
which divide rapidly and then differentiate into nondividing mature cell types such as
goblet cells, enterocytes, enteroendocrine cells and tuft cells (Figure 1-3) (Barker, 2014).
Wnt signaling is essential for maintaining and promoting the proliferation of ISCs which
are thought to be the cell of origin of colorectal cancer (White and Lowry, 2015). HIOs
have been shown to be self-renewing in culture while displaying markers of
differentiated intestinal epithelium when provided with the appropriate growth factors
suggesting that they recapitulate the different cell types found in the human intestine. It
is especially useful for us to study the MMR-dependent DNA damage response in the
tissue of origin and assess whether this response is active in normal human intestinal
cells and can play a role in tumor suppression in Lynch syndrome. Thus, in Chapter 3,
12

Figure 1-3.
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Figure 1-3. Architecture of the colon crypt.
LGR5+ stem cells at the crypt base generate rapidly proliferating TA cells in the lower
half of the crypt. TA cells subsequently differentiate into the mature lineages of the
surface epithelium (goblet cells, enterocytes, enteroendocrine cells and tuft cells).
Epithelial turnover occurs every 5–7 days.
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we have studied the MMR-dependent DNA damage response to alkylation damage in
HIOs to gain some insights into how loss of MMR may contribute to early events of
tumorigenesis in Lynch syndrome.

E. Senescence

Cellular senescence is a phenomenon where by proliferating cells permanently cease to
divide due to a variety of causes such as telomere dysfunction, oxidative stress, nontelomeric DNA damage, and oncogene activation. One possible consequence that has
been linked to senescence is aging, as the number of senescent cells is much higher in
old animals comparing to young animals during normal aging (Childs, 2015), and recent
evidence has shown that eliminating senescent cells can actually delay age-related
dysfunction (Baker, 2011). There is also strong evidence that cellular senescence is a
potent anticancer mechanism (Campisi, 2001; Braig, 2006; Prieur, 2008; Guerra, 2011).
Thus, senescence is commonly represented as a double-edged sword. Although
senescent cells can no longer replicate, they remain metabolically active and commonly
adopt an immunogenic phenotype consisting of a pro-inflammatory secretome. This
senescence

associated

secretory

phenotype

(SASP)

consisting

of

inflammatory cytokines, growth factors, and proteases is a highly characteristic feature
of senescent cells (Campisi, 2007). The SASP can have positive or negative effects on
cancer depending on the context. The SASP cytokines can reinforce the senescence
growth arrest and induce senescence in neighboring cells in a paracrine fashion. The
pro-inflammatory factors can also recruit immune cells to the local site and promote
immune clearance of the damaged cells (Xue, 2007; Chung, 2009). All of these are
15

beneficial in defense against cancer. On the other hand, these cytokines can also cause
epithelial-to-mesenchymal transitions which promote cancer (Sparmann, 2004; Tamm,
1994).In this study, we have examined whether the MNNG treatment induced
senescence in HIOs as a MMR-dependent DNA damage response to alkylation damage
in intestinal cells and the possible implication in tumorigenesis in Lynch syndrome.

CHAPTER 2

Human Pluripotent Stem Cells Have a Novel Mismatch Repair-Dependent Damage
Response
Lin B., Gupta D., Heinen C.D. (2014).J Biol Chem. 29;289(35):24314-24.

A. ABSTRACT

Human pluripotent stem cells (PSCs) are presumed to have robust DNA repair
pathways to ensure genome stability. PSCs likely need to protect against mutations
that would otherwise be propagated throughout all tissues of the developing embryo.
How these cells respond to genotoxic stress has only recently begun to be
investigated. Although PSCs appear to respond to certain forms of damage more
efficiently than somatic cells, some DNA damage response pathways such as the
replication stress response may be lacking. Not all DNA repair pathways, including
the DNA mismatch repair (MMR) pathway, have been well characterized in PSCs to
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date. MMR maintains genomic stability by repairing DNA polymerase errors. MMR is
also involved in the induction of cell cycle arrest and apoptosis in response to certain
exogenous DNA-damaging agents. Here, we examined MMR function in PSCs. We
have demonstrated that PSCs contain a robust MMR pathway and are highly
sensitive to DNA alkylation damage in an MMR-dependent manner. Interestingly,
the nature of this alkylation response differs from that previously reported in somatic
cell types. In somatic cells, a permanent G2/M cell cycle arrest is induced in the
second cell cycle after DNA damage. The PSCs, however, directly undergo
apoptosis in the first cell cycle. This response reveals that PSCs rely on apoptotic
cell death as an important defense to avoid mutation accumulation. Our results also
suggest an alternative molecular mechanism by which the MMR pathway can induce
a response to DNA damage that may have implications for tumorigenesis.

B. INTRODUCTION

Human pluripotent stem cells (PSC), including embryonic stem cells (ESC) and induced
pluripotent stem cells (iPSC) can replicate indefinitely in culture and give rise to all the
different somatic cell lineages. These features make PSCs attractive for their potential
use in regenerative therapy, and as a useful model system for drug screening,
genotoxicity testing and general mechanistic studies of development. The role of these
cells in the early stages of human development likely requires a strict maintenance of
genome stability to protect the developing embryo from the damaging effects of
mutations. Not surprisingly, some of the initial studies examining DNA repair pathways
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in PSCs indicate they are highly efficient at removing DNA damage compared to
somatic cells (Adams, 2010; Fung, 2011; Luo, 2012; Maynard, 2008). DNA damage
caused by gamma-irradiation (IR), ultra-violet irradiation (UV), H2O2 or the crosslinking
reagent psoralen are repaired more rapidly in hESC lines than in primary human
fibroblasts (Maynard, 2008).
However, in addition to damage repair, cells can respond to genotoxic stress through
the induction of protective cell cycle checkpoints. As an example, impeded replication
forks result in activation of an S-phase checkpoint which leads to stabilization of the
replication fork and coordination of DNA repair with the resumption of DNA synthesis
(Branzei, 2009). This important damage response protects the viability of the cell while
at the same time reduces the incidence of broken chromosomes which can lead to
genomic rearrangements. Interestingly, PSCs have been reported to lack this S-phase
checkpoint in response to replication stress (Desmarais, 2012). Rather PSCs upon
encountering replication stress are much more prone to apoptosis. This same increased
propensity to undergo apoptosis is also observed in PSCs treated with UV and IR (Luo,
2012; Qin, 2007; Wilson, 2010; Momcilovic, 2010;Filion, 2009). Understanding the
response of PSCs to different sources of genotoxic stress and the molecular
mechanisms involved becomes crucial if these cells are to ever realize their potential for
therapeutic purposes.

An important repair pathway that needs to be examined in PSCs is the DNA mismatch
repair (MMR) pathway. MMR increases the fidelity of DNA replication by up to three
orders of magnitude to maintain genome integrity through correcting DNA polymerase
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errors that escape proofreading (Kunkel, 2005; Kolodner, 1999;Modrich, 2006). Loss of
MMR function has been proposed to create a mutator phenotype in cells that increases
the risk of tumorigenesis (Fishel, 1995). Consistent with this hypothesis, germline
mutations in the major MMR genes are associated with the inherited cancer
predisposition disease Lynch syndrome (Lynch, 2009). Defects in MMR, mostly due to
epigenetic inactivation of the MMR gene MLH1, have also been associated with 10-40%
of sporadic colorectal and other cancer types (Dietmaier, 1997;Kane, 1997). In addition
to repairing DNA polymerase mistakes, the MMR pathway is also required for activation
of cell cycle checkpoints and apoptosis in response to certain DNA damaging agents
(Stojic, 2004a). For example, MMR-deficient cells are up to 100-fold more resistant to
the SN-1 alkylating agent Nmethyl-N’-nitro-N-nitrosoguanidine (MNNG) than isogenic
MMR-proficient cells (Cejka, 2003a; Kaina, 1997; Mastrocolaand Heinen, 2010a).
Studies in multiple cell lines have revealed that treatment with MNNG induces a MMRdependent G2 arrest in the second cell cycle after treatment (Kaina, 1997; Cejka,
2003b;Mastrocolaand Heinen, 2010b). It is not clear why it takes two cell cycles to
induce the G2 arrest. The primary cytotoxic lesion generated by MNNG is O6 methylguanine (MeG), which is commonly mispaired with T during replication. The
MeG–T mispair is recognized by the MMR heterodimer MSH2-MSH6 which activates
the MMR response (Duckett, 1996). Two major models have been proposed to explain
the molecular mechanism of this damage response. The “futile cycle” model suggests
that the MeG-T mispair generated during the first S-phase after treatment with MNNG
initiates the MMR process. Successful MMR is executed leading to excision of the
mispaired T in the daughter strand. However, as the modified MeG remains in the
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template strand, the polymerase will regenerate a MeG–T mispair again during repair
synthesis. The MMR process will be triggered repeatedly resulting in an unreplicated
gap opposite the lesion. In the next S-phase, the new replication fork encounters this
gap and converts it to a double strand break. It is this double strand break which
initiates a DNA damage response that ultimately leads to cell cycle arrest and eventual
apoptosis. The second model, the “direct signaling” model, suggests that, following
binding of the MeG-T mismatches by the MMR proteins a damage signal is transmitted
directly to the checkpoint machinery without the need for DNA processing. Evidence
supporting the direct signaling model includes findings that overexpression of MSH2 or
MLH1 induces apoptosis in either MMR proficient or deficient cells (Zhang, 1999), and
that checkpoint kinases Chk1, Chk2, ATR and ATM co-immunoprecipitate with MSH2 in
cell extracts after MNNG treatment (Adamson, 2005; Liu, 2010; Wang, 2003; Yoshioka,
2006).

In this study, we examined the activity of the DNA MMR pathway in human PSCs. We
were particularly interested in determining whether PSCs are capable of eliciting the
MMR dependent damage response to alkylation damage as observed in human cancer
cell lines and other somatic cell types. Our results reveal that iPSCs and ESCs are
hypersensitive to the alkylating agent MNNG, although the mechanism by which they
respond to the DNA damage is different. Our results demonstrate that the MMR
pathway is an important repair pathway for maintaining genome stability in human PSCs.
These results also reveal the need for further studies to fully understand the
mechanisms by which the MMR pathway can elicit a DNA damage response.
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C. MATERIALS AND METHODS

Cell Culture

Human ESCs (H1, CT-2) were obtained from the University of Connecticut Stem Cell
Core. Human iPSCs YK26 were reprogrammed from human dermal fibroblasts (HDFa)
using retroviral vectors as described (Zeng, 2010) and Rx13 were reprogrammed from
BJ human foreskin fibroblasts (HFF) using a single excisable polycistronic lentiviral
Stem Cell Cassette (STEMCCA) encoding the Yamanaka factors at the University of
Connecticut Stem Cell Core facility. Both ESCs and iPSCs were cultured on BD
Matrigel (BD Biosciences) with irradiated mouse embryonic fibroblast-conditioned ESC
media (GlobalStem) containing DMEM-F12, 20% knockout serum replacer (Invitrogen),
non-essential amino acids (NEAA, Invitrogen), 1mM L-glutamine (Invitrogen), 0.1mM
beta-mercaptoethanol (Sigma) and 4 ng/ml basic Fibroblast Growth Factor (bFGF,
Invitrogen). HDFa cells (ATCC) and human foreskin fibroblasts (HFF) (ATCC) were
cultured in DMEM containing 10% fetal bovine serum (FBS, Gibco), and NEAA. Hec59
cells (kind gift of Drs. Thomas Kunkel and Alan Clark) were grown in DMEM/F12
containing 10% FBS. HeLa cells (ATCC) were grown in DMEM containing 10% FBS.

Western Blotting

An equal number of H1, CT-2, YK26, Rx13, HDFa, HFF, HeLa or Hec59 cells were
harvested and lysed with RIPA buffer supplemented with protease inhibitors. The cell
lysates were separated by electrophoresis on a 6% SDS-polyacrylamide gel. The
primary antibodies used included: anti-MSH2 (BD #556349), anti- MSH6 (Bethyl A30021

023A), anti-MLH1 (BD #550838), anti-PMS2 (BD #556415), anti-PCNA (Santa Cruz sc56), anti-polδ (Santa Cruz sc- 10784), anti-RFC4 (Santa Cruz sc-20996), antiRPA
(Calbiochem RPA34-20), anti-phospho-Chk1 (Ser 345) (Cell Signaling #2341), antiphosphoChk2 (Thr 68) (Cell Signaling #2661), anti-Chk1 (Cell Signaling #2345), antiChk2 (Cell Signaling #2662), anti-γH2AX (Ser 139) (Millipore 05-636), anti-phospho-p53
(Ser15) (Cell Signaling #9284 ), anti-p53 (Cell Signaling # 9282), anti-phospho-ATM
(Ser 1981) (cell signaling #5883), anti-phospho-ATR (Ser 428) (cell signaling #2853),
anti-ATM (cell signaling #2873), anti-ATR (cell signaling #2790) and anti-actin (Sigma
A5060). Where indicated, cells were treated with 10 μM of the ATM-specific inhibitor
KU5593 (Selleck Chemicals) and/or the ATR-specific inhibitor VE- 821 (Selleck
Chemicals) for 24 hours prior to harvesting.

MNNG Treatment and Cell Cycle Analysis

MNNG (obtained from the National Cancer Institute Chemical Carcinogen Reference
Standard Repository; CAS: 70-25-7) was dissolved in DMSO to a concentration of 10
mM and stored at −20°C until use. O6 -Benzylguanine (O6 -BG; CAS: 19916-73-5) was
purchased from Sigma, dissolved in DMSO to a concentration of 25 mM and stored at
−80°C until use. Cells were treated with 25 μM O6 -BG for 2 hours, then media was
replaced with fresh media containing 25 μM O6 -BG and 2 μM MNNG for 48 hours. Cell
cycle analyses were performed using propidium iodide (PI) staining for DNA content
and subsequent detection by flow cytometry. Briefly, cells were harvested and fixed in
70% ethanol at −20°C. Cells were then treated with 20 μg/mL PI and 200 μg/mL RNase
A and incubated at 37°C for 1 hour, filtered, and analyzed with a FACS Calibur flow
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cytometer (BD Biosciences). The resulting data were analyzed by Modfit analysis
software.

MMR Knockdown

MMR knockdown YK26 cells were generated with lentiviral vectors containing shRNAs
targeting either MSH2 or MLH1. shMSH2 and sh-MLH1 lentiviruses were a kind gift
from Drs. Kareem Mohni and Sandra Weller. Briefly, YK26 cells were incubated with
lentivirus containing sh-MSH2 or sh-MLH1 for 1 hour, and then fresh medium was
added to continue incubation overnight. Stable expression of the shRNAs was
maintained by adding 0.8 μg/ml puromycin to the normal media.

Annexin V Staining and Apoptosis Analysis
YK26 cells were treated with 2 μM MNNG for 24 hours and then harvested and stained
with anti-Annexin V and PI using the Annexin V apoptosis kit (Molecular Probes
v13241). The cells were analyzed with a LSRII flow cytometer (BD Biosciences). The
resulting data were analyzed by FlowJo analysis software.

Cell Synchronization
Synchronization in mitosis was performed by treating YK26 cells with 0.2 μM
nocodazole for 18 hours. Cells were released in fresh medium containing 25 μM O6 BG. At four hours post release, cells were treated with 2 μM MNNG for an additional 4
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hours. Cells were harvested at different time points as indicated and subjected to cell
cycle analysis.

MMR Assay

The heteroduplex MMR substrate was prepared according to Zhou et al., (Zhou, 2009).
The p111 and p189 plasmids were a kind gift from Dr. LuZhe Sun. p189 encodes for a
premature stop codon in the EGFP gene. To generate single-stranded (ss) DNA circles,
p111 was nicked with Nb.Bpu10I (Thermo Scientific) and further digested with ExoIII
(New England Biolabs). The heteroduplex substrate was prepared by annealing the
ssDNA circles to linearized, denatured p189 DNA. Excess linear DNA and ssDNA were
removed by plasmid-safe DNase (Epicentre Biotechnologies). To assess MMR activity,
PSCs were transfected with 2.5 μg of the heteroduplex plasmid and 2.5 μg of pDsRed2N1 (Clonetech) which encodes the red fluorescent protein (RFP) using the Amaxa
Human Stem Cell Nucleofector kit 2 (Lonza VPH- 5022). HeLa cells were transfected
using Lipofectamine2000 (Invitrogen) and HDFa cells were transfected using GeneIn
transfection reagent (GlobalStem). After incubation for 48 hours the cells were
harvested and analyzed for fluorescence intensity with a LSRII flow cytometer (BD
Biosciences) using BD FACS Diva software. The ratio of GFP-positive cells to RFPpositive cells was determined to account for differences in transfection efficiency.

Immunofluorescent staining
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H1 cells with or without MNNG treatment were fixed with 4% paraformaldehyde for 10
minutes, and permeablized with cold acetone for 2 minutes. After blocking in
1%BSA/PBS for 1 hour at room temperature, cells were incubated with the diluted
primary antibodies anti-cleaved caspase-3 (BD #559565) and anti-cleaved caspase-9
(Pierce #PA5-17913) for 1 hour at room temperature then incubated with diluted Alexa
Fluor 488 secondary antibody (Molecular Probes) for 45 minutes at room temperature.
Nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI) and cells were
analyzed on a Nikon Eclipse Inverted Fluorescent microscope.

D. RESULTS

The MMR proteins are highly expressed in PSCs compared to parental fibroblasts

To begin characterizing the MMR pathway in iPSCs, we first examined the expression
of the four major MMR proteins, MSH2, MSH6, MLH1 and PMS2. Whole cell extracts
were prepared from an equal number of human dermal fibroblasts (HDFa), human
foreskin fibroblasts (HFF), human ESCs (H1, CT-2) and human iPSCs (YK26
reprogrammed from HDFa, Rx13 reprogrammed from BJ foreskin fibroblasts).
Consistent with previous reports of increased MMR gene expression in iPSCs
(Momcilovic, 2010), we showed that the expression of all four MMR proteins are
increased 5-8 fold in YK26 cells compared to the parental HDFa cells (Fig.2-1A) and
similarly increased in H1 and Rx13 cells compared to HFF cells (Fig.2-1B). The
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Figure 2-1.

26

Figure 2-1. Human pluripotent stem cells express higher levels of MMR proteins
than parental fibroblasts.
A, Western blot analysis of mismatch repair (MMR) proteins in an equal number of
human embryonic stem cells (H1, CT-2), human induced pluripotent stem cells (YK26,
Rx13) and parental fibroblasts (HDFa). B, Western blot analysis of MMR proteins in an
equal number of H1, Rx13 and human foreskin fibroblasts (HFF).C, Western blot
analysis and quantitation of MMR proteins in HeLa, Hec59 and YK26 cells.D, Western
blot analysis of various replication proteins in H1, YK26, and HDFa cells. The values
represent the means of three independent experiments.
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expression between the different iPSCs and ESCs was similar (Fig. 2-1A and 2-1B).
PSCs undergo rapid cell division compared to both fibroblast lines, so we compared
expression of the MMR proteins in the PSC lines to a more proliferative cell type. We
found that the levels of MSH2, MSH6 and MLH1 in YK26 cells were 1.5-2 fold higher
than in the MMR-proficient HeLa cervical cancer cells, while PMS2 levels were similar
(Fig. 2-1C). These results suggest that PSCs may have a robust MMR system to protect
their genome. We also found that essential replication proteins such as PCNA, Pol δ,
and RFC4 were expressed at higher levels in PSCs compared to fibroblasts, though
levels of RPA were similar between the cell types (Fig. 2-1D).

PSCs repair mismatches more efficiently than parental fibroblasts

Considering the increased expression of MMR proteins in PSCs, we asked whether
their single basepair mismatch repair capacity is enhanced compared to the parental
fibroblasts. To test repair activity, we introduced a plasmid into cells that encodes GFP
containing a single G-T mispair that disrupts protein translation (Zhou, 2009). In vivo
repair of the mismatch leads to restored GFP expression that can be quantitated using
flow cytometry. As a control for transfection efficiency, cells were co-transfected with an
RFP-expressing plasmid. We found that the majority of transfected ESCs and iPSCs
expressed GFP indicating robust repair of the heteroduplex substrate (Fig. 2-2A and 22B). This repair efficiency was significantly enhanced over parental HDFa cells. The
repair rate in PSCs was similar to MMR-competent HeLa cells (Fig. 2-2A and 2-2B). To
confirm that restoration of GFP expression is MMR dependent, we used lentiviral
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Figure 2-2. Human pluripotent stem cells repair mismatches more efficiently than
parental fibroblasts.
Repair of a transfected heteroduplex plasmid encoding GFP with a premature stop
codon and RFP as a transfection control as measured in HeLa, H1, CT-2, YK26, Rx13
and HDFa cells. A, Representative flow cytometry images. B, Quantitation of repair
rates in transfected cells. * represents pvalue < 0.01.C, Western blot analysis confirming
the knockdown of MSH2 or MLH1 in YK26. Actin is included as a loading control. D,
The percentage of heteroduplex repair in control and MSH2 or MLH1 knockdown (KD)
YK26 cells. The values represent the means of three independent experiments. *
represents p-value < 0.01.
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vectors encoding shRNAs to knockdown levels of MSH2 or MLH1 in the YK26 cells (Fig.
2-2C). Knockdown of MSH2 or MLH1 also resulted in loss of stability of their obligate
heterodimer partners MSH6 and PMS2, respectively. Knockdown of MSH2 did not
affect levels of MLH1-PMS2, nor did MLH1 knockdown alter levels of MSH2- MSH6 (Fig.
2-2C). We found that the levels of repair in either MSH2 knockdown or MLH1
knockdown YK26 cells was 2-2.5 fold reduced compared to YK26 cells infected with a
luciferase shRNA expressing lentivirus (Fig. 2-2D). These results reveal that PSCs have
robust MMR repair function compared to differentiated cell types that is similar to that
observed in highly proliferative cancer cells.

PSCs are hypersensitive to the alkylating agent MNNG

To test whether PSCs have the protective MMR-dependent response to alkylation
damage, we treated ESCs and iPSCs, along with HeLa cells (MMR proficient), Hec59
endometrial cancer cells (MMR deficient, see Fig. 2-1C), and HDFa cells with 2 μM
MNNG for 48 hours. Cells were pretreated with the methylguanine methyltransferase
inhibitor O6 -BG for 2 hours to enhance the effects of the alkylation damage. The cells
were examined by flow cytometry to determine whether MNNG induces a cell cycle
arrest. Consistent with our previous studies (Mastrocola and Heinen, 2010a; 2010b),
HeLa cells were permanently arrested at G2/M after MNNG treatment, while no cell
cycle arrest was observed in the MMR-deficient Hec59 cells (Fig. 2-3A). Surprisingly,
while we did not see any evidence for a G2/M arrest in either the iPSC or ESC lines, we
observed large sub-G1 peaks consistent with the cells undergoing apoptosis (Fig. 2-3A
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Figure 2-3. DNA alkylation damage induces apoptosis in human pluripotent stem
cells.
A, Representative cell cycle profiles of HeLa, Hec59, CT-2, YK26, and HDFa cell lines
with or without 2 μM N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) for 48 hours as
measured by flow cytometry. The arrows indicate the presence of sub-G1 populations,
associated with apoptotic cells. B, Representative cell cycle profiles of H1 and Rx13
cells with or without 2 μM MNNG for 48 hours. C, Representative cell cycle profiles of
HDFa cells with or without 2 μM or 5 μM MNNG for 5 days. D, Representative cell cycle
profiles of YK26 cells mock treated or treated with 2 μM or 0.2 μM MNNG.
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and 2-3B). The fibroblasts from which the YK26 iPSCs were derived did not show any
apoptosis and only a modest G2/M arrest after MNNG treatment. As the HDFa cells
replicate more slowly than PSCs and HeLa cells, we incubated them for an additional
72 hours following treatment to ensure that the cells could finish the two cell cycles
necessary to undergo a G2/M arrest consistent with the futile cycle model. We also
tested a higher dose of MNNG. These changes led to slightly increased populations of
cells in G2/M, but still not the dramatic response observed in HeLa cells suggesting that
the MMR-dependent response to alkylation damage is not very strong in HDFa cells
(Fig. 2-3C). On the other hand, treatment of iPSCs with a ten-fold lower concentration of
MNNG for 48 hours still resulted in a substantial sub-G1 population (Fig. 2-3D). These
results highlight the extent to which the iPSCs re-activate the alkylation damage
response during reprogramming.

The alkylation damage response is MMR dependent

We next tested whether the response to MNNG in PSCs is MMR dependent by
comparing the damage response between control and MMR knockdown iPSCs. We
treated the control and MMR knockdown iPSCs with 2 μM MNNG and analyzed their
cell cycle profiles. The MNNG induced apoptotic response was entirely abrogated in the
MSH2 or MLH1 knockdown lines suggesting that the hypersensitive response of PSCs
to alkylation damage is MMR dependent (Fig. 2-4A). To confirm that the sub-G1
populations observed in the cell cycle profiles are apoptotic PSCs, we used an apoptotic
marker Annexin V to detect apoptotic cells. We found that after MNNG treatment most
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Figure 2-4. The apoptotic response to alkylation damage in induced pluripotent
stem cells is mismatch repair dependent.
A, Representative cell cycle profiles of control, MSH2 or MLH1 knockdown YK26 cells
with or without 2 μM MNNG for 48 hours by flow cytometry. B, Annexin V and propidium
iodide (PI) staining of control, MSH2 or MLH1 knockdown YK26 cells with or without 2
μM

MNNG

treatment

for

24

hours

as

analyzed

by

flow

cytometry.

C,

Immunofluorescence imaging of cleaved caspase-9 and cleaved caspase-3 in H1 cells
with or without 2 μM MNNG treatment for 24 hours.

36

of the control YK26 cells were dually-positive for Annexin V and PI, while a majority of
the MSH2 or MLH1 knockdown YK26 cells were negative for Annexin V and PI staining
(Fig. 2-4B). We also observed activation of caspase-9 and caspase-3 in MNNG-treated
YK26 cells by immunofluorescence (Fig. 2-4C). These results demonstrate that PSCs
respond to MNNG by inducing an intrinsic apoptotic pathway that is MMR dependent.

MNNG-induced apoptosis occurs in the first S phase after damage without
undergoing G2 arrest

Previous studies have shown that MNNG induces a MMR-dependent G2/M arrest in the
second cell cycle after treatment in multiple somatic cell types, and this permanent
G2/M arrest eventually leads to apoptosis (Kaina, 1997; Cejka, 2003b; Mastrocola and
Heinen, 2010b). In both the ESCs and iPSCs, we observed apoptosis after MNNG
treatment without any apparent G2/M arrest. We speculated that due to the rapid
proliferation rate of PSCs, it was possible the cells underwent a G2/M arrest prior to
apoptosing that we failed to observe due to the timing of our experiment. To assess the
timing of the response, we synchronized YK26 cells in mitosis with the microtubule
inhibitor nocodazole. The cells were then released back into the cell cycle in normal
growth media. At 4h post release when most cells were in G1 phase, we treated them
with 2 μM MNNG for an additional 4 hours. We returned the cells to normal media again
and harvested them at different time points for cell cycle profile analysis (Fig. 2-5). We
observed that our mock treated cells were beginning to enter S-phase 8 hours after
release from the nocodazole block and by 16 hours they had all cycled through to G2/M.
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Figure 2-5. MNNG-induced apoptosis occurs in a mismatch repair-dependent
manner in the first S-phase after damage.
Representative cell cycle profiles of control or MSH2 knockdown YK26 cells originally
synchronized in mitosis by nocodazole as measured by flow cytometry. Cells were
released into normal growth media and then, with or without a 4 hour treatment of 2 μM
MNNG, harvested at different time points after release. The arrows indicate sub-G1
populations of cells. The absence of subG1 populations observed in MSH2 knockdown
cells indicates a loss of the apoptotic response observed in control cells.
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By 24 hours post-release, the cells were continuing through the cell cycle in an
asynchronous fashion. Similarly, our MNNG treated cells were also entering S-phase at
the 8 hour time point; however, we observed a fraction of the cells in a sub-G1
population. By 16 hours, the treated cells remained mostly in S-phase suggesting a
delay in progression through S-phase compared to the untreated cells. A sub-G1 peak
was also evident at 16 hours. By 24 hours, the sub-G1 peak had diminished and the
surviving cells continued through the cell cycle. To determine whether the cells incur a
G2/M arrest after the second cell cycle following MNNG treatment, we harvested treated
cells at 48 and 72 hours post-release, but did not observe any cell cycle arrest. We
confirmed that the observed apoptotic response to MNNG was MMR-dependent by
repeating the synchronization experiments in our MMR knockdown YK26 cells. As
observed in our asynchronous populations, the sub-G1 peak following MNNG treatment
is absent in the MSH2 and MLH1 knockdown iPSCs (Fig. 2-5).

Unlike the 48 hour MNNG treatment of PSCs which resulted in nearly 85% of the cells
apoptosing (Fig. 2-4B), a 4 hour treatment resulted in the death of only a fraction of the
cells. To test whether we had selected for a population of cells that can tolerate this
treatment level, we allowed the surviving cells to recover in normal growth media for 24
hours before subjecting them to a second round of MNNG treatment for 4 hours. If the
initial treatment led to a selection of resistant cells, we would not expect any response
to the second round of MNNG. However, we once again observed that a similar fraction
of cells displayed a sub-G1 peak, indicative of apoptosis (Fig. 2-6). Taken together,
these results suggest that PSCs undergo an immediate apoptotic response to MNNG in
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Figure 2-6.

Figure 2-6. Pluripotent stem cells that survive MNNG treatment retain sensitivity
to MNNG.
Synchronized YK26 cells were treated with 2 μM MNNG for 4 hours (1st treatment).
Cells were allowed to recover in fresh media for 24 hours, then treated again with 2 μM
MNNG for 4 hours (2nd treatment). Cell cycle profiles of synchronized YK26 after 1st
and 2nd treatment are displayed.
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the first S-phase after treatment without undergoing a G2/M arrest first. This result is
very different from the response observed in HeLa and other somatic cell types.

DNA damage checkpoint kinases are not activated in iPSCs in response to MNNG

Previous studies of the MMR damage response indicate activation of the checkpoint
kinases Chk1 and Chk2 following MNNG treatment that may be responsible for the cell
cycle arrest and cell death observed (Mastrocola and Heinen, 2010b;Noonan, 2012;
Stojic, 2004b). We wanted to test whether the checkpoint kinases are activated in PSCs
after MNNG treatment. Asynchronous iPSCs or HeLa cells were mock treated or treated
with MNNG for 24 hours and then harvested one day later. We found that HeLa cells
treated with MNNG resulted in robust activation of Chk1 and Chk2 as indicated by
phosphorylation of Ser 345 and Thr 68, respectively (Fig. 2-7A). No activation of either
Chk1 or Chk2 was observed in iPSCs after MNNG treatment (Fig. 2-7A). To confirm
that this response was consistent across multiple PSC lines, we performed similar
experiments in Rx13 iPSCs and the two ESC lines. As in YK26 cells, MNNG treatment
failed to activate Chk1 and Chk2 in this panel of PSCs (Fig. 2-7B). To rule out a
transient activation of Chk1 or Chk2 early in the response to damage, we repeated the
synchronization experiments described previously and analyzed cell extracts at different
time points. We found no significant activation of Chk1 and Chk2 at any point during the
cell cycle following MNNG treatment (Fig. 2-7C and 2-7D). However, we did observe a
strong induction of γH2AX which is indicative of double strand breaks and/or replicative
stress in the first S phase coinciding with the sub-G1 peaks (Fig. 2-7C and 2-7D). These
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results indicate that the typical checkpoint kinases activated during the MMR-dependent
damage response in somatic cells are not involved in the PSCs response to alkylation
damage, again suggesting a different damage response mechanism is employed in
these cells.

p53 is induced and activated in iPSCs after MNNG treatment

PSCs treated with the DNA damaging agent etoposide, undergo a rapid and extensive
induction of apoptosis that is abrogated by knocking down p53 (Grandela, 2007). To
test whether p53 is activated in PSCs after MNNG treatment, we examined MNNG
treated iPSC lysates for increased levels of total p53 protein and increased phosphop53 (Ser 15) levels. We found that both p53 and phospho-p53 levels were increased in
iPSCs after a 24 hour MNNG treatment, however, there was no induction or activation
of p53 in MSH2 knockdown YK26 cells (Fig. 2-7E and 2-7F). We observed a similar
MNNG-induced activation of p53 in the other iPSC and ESC lines tested (Fig. 2-7B).
These results indicate that MNNG treatment causes a MMR-dependent activation of
p53 in PSCs, which may be responsible for the apoptosis observed.

ATM and ATR are involved in the MNNG-induced phosphorylation of p53

Activation of p53 following DNA damage can result from direct phosphorylation by the
phosphatidylinositol 3-kinase-related kinases (PIKKs) ataxia teleangectasia mutated
(ATM) (Banin, 1998;Canman, 1998) or ataxia teleangectasia mutated and Rad3 related
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Figure 2-7. Chk1 and Chk2 are not activated in induced pluripotent stem cells in
response to MNNG, but p53 is.
A, Western blot analysis of phospho-Chk1, phospho-Chk2, total Chk1 and total Chk2 in
HeLa and YK26 cells with or without 2 μM MNNG treatment for 24 hours. B, Western
blot analysis of phospho-Chk1, phospho-Chk2, total Chk1, total Chk2, phospho-p53 and
total p53 in H1, CT-2 and Rx13 cells with or without 2 μM MNNG treatment for 24 hours.
C, Western blot analysis of phospho-Chk1, phospho-Chk2, total Chk1, total Chk2 and γ
H2AX in YK26 cells originally synchronized in mitosis with nocodazole then, with or
without a 4 hour treatment of 2 μM MNNG, harvested at different time points after
release. D, Quantitation of Western blots represented in C. The values represent the
means of three independent experiments. E, Western blot analysis of phospho-p53
(Ser15) and total p53 in control or MSH2 knockdown YK26 cells with or without 2 μM
MNNG treatment for 24 hours. Actin is included as a loading control. F, Quantitation of
Western blots represented in E. The values represent the means of three independent
experiments.
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(ATR) (Tibbetts, 1999). To test whether these PIKKs were involved in the response to
alkylation damage, we first examined MNNG treated YK26 and H1 cells for the
presence of Ser 1981 phosphorylation of ATM (Bakkenist, 2003) and Ser 428
phosphorylation of ATR (Liu, 2011) as markers for DNA damage-dependent activation.
We found that both ATM and ATR are phosphorylated following MNNG treatment of
PSCs (Fig. 2-8A). ATR phosphorylation is similar to that observed in HeLa cells,
however, ATM phosphorylation is not as enhanced in PSCs as HeLa. We next asked
whether inhibiting the activity of ATM or ATR affected p53 induction and
phosphorylation. We treated H1 cells with the ATM-specific inhibitor KU55933 or the
ATR-specific inhibitor VE-821 along with MNNG for 24 hours and found that treatment
with both inhibitors led to a partial reduction in the levels of damaged-induced total and
phosphorylated p53 (Fig. 2-8B). When combining both inhibitors, we saw an additive
effect as the levels of p53 activation were reduced even further then with either single
agent alone. However, complete inhibition of p53 induction or phosphorylation was
never observed which may suggest other kinases, such as DNA-PK, may be involved.
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Figure 2-8. MNNG treatment leads to phosphorylation of ATR and ATM in
pluripotent stem cells.
A, Western blot analysis of phospho-ATM (Ser 1981), phospho-ATR (Ser 428), total
ATM and total ATR in H1, YK26 and HeLa cells with or without 2 μM MNNG treatment
for 24 hours. (Experiment performed by Dipika Gupta.) B, Western blot analysis of
phospho-p53 and total p53 in H1 cells treated with 2 μM MNNG and the ATM-specific
inhibitor KU5593 or the ATR-specific inhibitor VE-821 or both for 24 hours. The values
represent the means of three independent experiments.
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E. DISCUSSION

Our results show that PSCs including both iPSCs and ESCs have a robust MMR
pathway to protect the stability of their genome. Expression of the four major MMR
proteins is greatly enhanced compared to primary fibroblasts from which our iPSCs
were derived and slightly enhanced compared to rapidly dividing HeLa cancer cells.
This is consistent with the upregulation of other DNA repair factors observed in PSCs
compared to more differentiated cell types. Increased expression of factors involved in
homologous recombination repair (HRR) such as RAD51 and BRCA1, non-homologous
end joining such as Ku70 and base excision repair (BER) such as UNG and FEN1 has
been reported in PSCs (Maynard, 2008; Momcilovic, 2010;Fan, 2011). The enhanced
expression of DNA repair proteins in PSCs may underlie the increased repair efficiency
observed in these cells. PSCs display accelerated repair of cyclobutane pyrimidine
dimers caused by ultraviolet (UV) radiation, suggesting an enhanced nucleotide
excision repair pathway (Luo, 2012; Maynard, 2008). Repair of modified bases caused
by treatment with hydrogen peroxide or dimethyl sulfate is improved in PSCs compared
to somatic cell types, suggesting enhanced BER (Luo, 2012; Maynard, 2008). Double
strand breaks caused by hydrogen peroxide or gamma irradiation are repaired more
efficiently in PSCs than in somatic cells (Adams, 2010;Luo, 2012; Maynard, 2008; Fan,
2011). Similarly, we detected high levels of single base pair mismatch correction by the
MMR pathway in iPSCs and ESCs. Thus, the enhancement of DNA repair pathways
appears to be an important strategy that PSCs employ to protect their genome.
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However, increased expression of repair factors may not always promote increased
DNA repair. The levels of MMR proteins expressed in PSCs were slightly higher than in
HeLa cells, yet the repair activity in PSCs was slightly reduced compared to the cancer
cells. These results may suggest that at the high expression levels observed in both
PSCs and HeLa cells, the amounts of the four major MMR proteins are no longer rate
limiting in the repair process. Localization of the MMR proteins to the mismatched
template or the availability of other proteins involved in repairing the mismatch may be
limiting. Alternatively, as 80% or more of the transfected mismatched template are
repaired in PSCs, we may be reaching the limitations of the assay to discern repair
efficiency.

Another important strategy used by PSCs to prevent mutation is an increased
hypersensitivity to DNA damage. Increased apoptosis has been observed in PSCs
treated with a variety of DNA damaging agents including UV (Luo, 2012; Qin, 2007),
gamma irradiation (Wilson, 2010; Momcilovic, 2010;Filion, 2009; Fan, 2011), cisplatin
(Desmarais, 2012) and thymidine (Desmarais, 2012). Our results show that PSCs
undergo massive apoptosis in response to the alkylating agent MNNG. Interestingly,
Figure 2-4B also reveals an increased level of background apoptosis in untreated iPSCs
compared to MMR knockdown iPSCs. These results may suggest sensitivity to even
endogenously-generated DNA damage in a MMR-dependent manner. Alternatively, the
high proliferation rate of PSCs may increase mismatch formation which, if a certain
threshold is reached, may result in replication stress due to the excessive MMR activity.
As PSCs are particularly sensitive to replicative stress (Desmarais, 2012), this may lead
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to increased cell death. While such a mechanism has not been described in somatic
cells, yeast displaying a mutator phenotype due to mutations in polymerase δ havebeen
shown to have prolonged S-phase and evidence of a G2/M arrest consistent with
replication stress signals due to increased mutation generation (Venkatesan, 2006).

Whereas somatic cell types have also been shown to be sensitive to MNNG in a MMR
dependent fashion, we show here that the commitment to cell death occurs much more
quickly in PSCs. Somatic cells treated with MNNG require two rounds of S-phase
following treatment resulting in a G2/M arrest and, eventually, cell death. Why two cell
cycles are necessary is not entirely clear, however, the futile cycle model suggests that
MMR processing of MeG–T mismatches in the first S-phase results in persistent
unreplicated gaps that are converted to lethal double strand breaks in the second Sphase (Fig. 2-9). One potential implication is that the two cell cycles provide an
increased opportunity to resolve the primary MeG lesion. For example, cells suffering
low levels of MeG damage may be protected against its mutagenic effects by the MMR
pathway until MGMT is able to remove the MeG lesion. Repair of the unreplicated
region caused by MMR processing at a later time point would allow the cell to ultimately
survive. Accumulating evidence suggests that somatic cells are capable of exiting Sphase with incompletely replicated chromosomes and may be able to repair these
regions during the subsequent cell cycle (Mankouri,2013). Cells undergoing replicative
stress are marked in the following G1-phase by large, 53BP1 foci that may play a role in
shielding unreplicated gaps until they can be repaired during the next S-phase (Harrigan,
2011; Lukas, 2011). Even if the unreplicated regions go unrepaired and are converted
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to double strand breaks, the breaks could be a substrate for HRR, again leading to cell
survival. Consistent with this model, depletion of the HRR protein Rad51d in mouse
embryonic fibroblasts resulted in a fivefold increased sensitivity to MNNG compared to
wild-type cells (Rajesh, 2010). This increased sensitivity was alleviated when MLH1 was
also depleted, indicative of HRR playing a role in resolving secondary damage
generated by MMR-lesion processing. The immediate apoptotic response observed in
PSCs suggests that these cells do not have any extra time to resolve the alkylation
damage.

One possibility that will require further investigation is that PSCs, unlike somatic cells,
cannot tolerate perturbed S-phase progression such as might occur during futile cycles
of MMR (Fig. 2-9). PSCs have already been shown to lack intra-S phase checkpoints in
response to replication stress that normally function to stabilize replication forks and
allow for replication re-start (Desmarais, 2012). In the current study, we observed a
similar failure of PSCs to activate Chk1 in response to MNNG, thus missing a possibly
important signaling pathway by which somatic cells survive MMR processing of MeG–T
mismatches in the first S-phase (Noonan, 2012). Therefore, the futile MMR cycling at
MeG–T mismatches may result in replication stress through either stalled polymerase
forks or the generation of unreplicated single-stranded gaps that lead to immediate
apoptosis induction. Interestingly, we do see an increase in γ-H2AX activation in the first
S-phase after damage which has been associated with increased replication stress
(Sirbu,2011). Alternatively, the MMR proteins may be functioning through a direct
signaling mechanism to recruit stress response proteins to the sites of damage. We
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Figure 2-9.

Figure 2-9. Model of the mismatch repair-dependent damage response to
alkylation damage in somatic cells versus human pluripotent stem cells. Details
described in text.
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have shown that MNNG results in the phosphorylation of ATM and ATR as well as the
MMR-dependent stabilization and activation of p53, which unlike in somatic cells
(Noonan, 2012), leads to cell death during the first S-phase in PSCs. The explanation
for this differing outcome between cell types may come from recent data showing that
ESCs have an enhanced mitochondrial readiness for apoptosis compared to more
differentiated cell types (Liu, 2013). Although p53 activation is similar between ESCs
and differentiated cells following treatment with the radiomimetic drug neocarzinostatin,
the balance of pro- and anti-apoptotic proteins in ESCs is such that they are more prone
to undergo apoptosis.

Our results raise interesting questions about the molecular pathways involved in the
apoptotic response to MNNG in PSCs. Both ATM and ATR are involved in activating
p53. Inhibiting both kinases reduces the level of p53 activation, though it does not
eliminate p53 activation entirely. Whether the increased activation of p53 by multiple
kinases is required to induce an apoptotic response or whether the overlap provides a
fail-safe mechanism to ensure p53 activation and apoptosis upon damage is not clear.
In addition, it is not clear why ATM and ATR activation are not accompanied by
activation of Chk1 and Chk2. Determining whether Chk1 and Chk2 are prevented from
being phosphorylated by the PIKKs or whether they are phosphorylated and rapidly
turned over is an important mechanistic question for determining how PSCs respond to
replicative stress.
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Understanding the mechanisms by which PSCs handle genotoxic stress will be
extremely important if these cells are to realize their full potential as therapeutic agents
in regenerative medicine. In addition, our results may provide insight into the role of the
MMR pathway in preventing tumorigenesis. An important question that our studies raise
is whether adult stem cells and cancer stem cells behave more like PSCs with regard to
their MMR-damage response or more like differentiated cells in culture. If they are
similar to PSCs, the increased sensitivity to DNA damage may result in a strong
selection pressure for loss of MMR function. We have previously proposed that colonic
stem cells from Lynch syndrome patients, which are heterozygous for a given MMR
gene, may be under selection pressure to lose the remaining wild-type allele when
exposed to DNA damaging agents in the colonic environment, thus enhancing
tumorigenesis (Heinen, 2002). The damage response mechanism may also have
implications for tumor response to therapy. If cancer stem cells do not share the same
rapid apoptotic response to damage with PSCs, it is possible that their response may be
made more similar to PSCs by priming the cells for apoptosis through the use of
antiapoptotic protein inhibitors (Liu, 2013). More studies will be required to better
understand the MMR damage response in multiple cell types, however, our results
reveal the utility of using PSCs for drug response testing.
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CHAPTER 3

The Use Of Human Intestinal Organoids To Study The Effects Of Early CancerCausing Mutations On intestinal Stem Cells

A. ABSTRACT

Lynch syndrome is a hereditary disease predisposing patients to colorectal and other
cancers, caused by germline mutations in DNA mismatch repair (MMR) genes. How
loss of MMR contributes to cancer is still unclear. The MMR pathway preserves genome
fidelity following DNA replication and induces apoptosis and cell cycle arrest in cancer
cells in response to DNA damage. We tested how this MMR-dependent damage
response affects normal human intestine using human intestinal organoids and found
that intestinal cells undergo not only apoptosis, but also a novel senescence response
and accelerated differentiation in a MMR-dependent manner following alkylation
damage. The cells undergoing apoptosis are primarily the intestinal stem cells
suggesting different cell types in the intestine have different responses to damage.
Together these results indicate that loss of MMR function in the intestinal crypts may
provide a selective advantage that contributes to tumorigenesis particularly in the
context of increased DNA damage.
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B. INTRODUCTION

Lynch syndrome (LS)is a hereditary syndrome predisposing patients to a spectrum of
cancers, primarily colorectal cancer (CRC) (Lynch et al., 2015). With a > 80% lifetime
risk of developing CRC, these patients would benefit from improved prevention
measures such as chemoprevention, though chemopreventative strategies for LS
patients to date have been largely unsuccessful (Ricciardiello et al., 2016). An improved
understanding of how intestinal cells are impacted by early cancer-causing mutations
would aid such an effort. An early change in LS CRC is loss of DNA mismatch repair
(MMR) function. LS is caused by germline mutations in one copy of a DNA MMR gene
(Lynch et al., 2015). Cancer development is preceded by somatic loss of the remaining
wild-type allele most likely in an intestinal stem cell (ISC) which is thought to be the cell
of origin of CRC (White and Lowry, 2015). How loss of MMR function contributes to
tumorigenesis is still not entirely clear. The MMR pathway repairs mistakes made by the
DNA polymerase during replication with MMR loss increasing the mutation rate nearly
1,000-fold (Kolodner, 1996; Modrich, 1991; Strand et al., 1993).Thus, MMR-defective
cells develop a mutator phenotype that increases the risk of mutation in other important
oncogenes and tumor suppressors (Fishel and Kolodner, 1995). In addition, the MMR
pathway is involved in inducing apoptosis and cell cycle arrest in cancer cell lines in
response to certain DNA damaging agents(Li et al., 2016; Stojic et al., 2004). Whether
this response is active in normal human intestinal cells and plays a role in tumor
suppression is an important unanswered as a suitable model system for studying the
effects of cancer-causing mutations on human intestinal cells is lacking.
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The recent development of three-dimensional human tissue organoids may provide a
powerful new model for answering this question. Human intestinal organoids (HIOs)
have been created from intact intestinal crypts as well as through the directed
differentiation of human embryonic stem cells (hESCs) (Cao et al., 2011; Sato et al.,
2011; Spence et al., 2011). HIOs are self-renewing and display markers of differentiated
intestinal epithelium suggesting that they recapitulate the different cell types found in the
human intestine. Here, we have used wild-type and MMR-knockout hESCs as well as
adult colon tissue to create HIOs for studying the MMR-dependent damage response to
DNA alkylation damage in normal human intestinal cells. We find that different intestinal
cell types undergo different MMR-dependent responses to DNA damage.

C. MATERIALS AND METHODS

Differentiation of hESC-derived HIOs
H1 hESCs were maintained on Matrigel-coated tissue culture plates in hESC media.
hESCs were differentiated into HIOs as previously described (McCracken et al., 2011)
except for addition of 6 μMof the GSK3β inhibitor CHIR99021 to definitive endoderm
cells to form hindgut spheroids. Briefly, H1 ESCs were differentiated to definitive
endoderm (DE) by addition of Activin A (100 ng/ml; R&D Systems) for three days in
RPMI 1640 media (Gibco) containing increasing concentrations (0%, 0.2%, and 2.0%)
of defined fetal bovine serum (dFBS).Following DE induction, cells were cultured in
DMEM/F12 media (Lonza) with B27 (Invitrogen) and the GSK3β inhibitor CHIR99021
(6μM; Selleck Chemicals) for 4 days to form hindgut spheroids. The media was
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changed every day. Spheroids were collected, resuspended in 50μl Matrigel (BD
Biosciences), and plated in a three-dimensional droplet. After Matrigel was allowed to
solidify for 10–15 minutes in a tissue culture incubator, spheroids were overlaid with
HIO media: DMEM/F12 with B27, EGF (100ng/ml; R&D Systems), noggin (100ng/ml;
R&D Systems) and R-spondin1 (500ng/ml; R&D Systems). Media was replaced every 3
days. Following 2 weeks, HIOs were collected and re-plated in fresh Matrigel at a
dilution of 1:6.

MSH2 Knockout in hESCs

MSH2 knockout hESCs were derived using CRISPR/Cas9 gene editing with a guide
RNA targeting the first exon of MSH2. Briefly, the guide RNA was cloned into the
Px459V2.0 vector. H1 hESCs were treated with 10 μM ROCK inhibitor Y-27632 (Selleck
Chemicals) for 2h before nucleofection. One million cells were nucleofected (Amaxa2b,
program B-016) with 2μg of the vector DNA expressing the guide RNA, the Cas9 cDNA
and a puromycin resistance gene. Transfected cells were selected with 0.5μg/mL
puromycin starting 24h after nucleofection for 2 days. After 2 days of selection, fresh
medium was added daily and the single cell clones were picked 12-15 days later. Single
cell clones were screened via Hot Shot DNA isolation and PCR and restriction enzyme
analysis to determine disruptions near the target site. Clones identified with a positive
PCR screen were verified by genomic DNA sequencing as well as by Western blot to
check for loss of MSH2 protein expression.

Generation of LGR5-eGFP HIOs
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The LGR5-eGFP BAC, kindly provided by Dr. Jason Spence (McCracken et al., 2014),
was nucleofected into single cell suspensions of H1 hESCs using the Amaxa Human
Stem Cell Nucleofector Starter Kit. Cells were grown in G418 (200μg/ml) for two weeks
to select for cells that took up the BAC. G418-resistant H1 ESCs were maintained in
antibiotic indefinitely. LGR5-eGFP H1 ESCs were differentiated into HIOs as described
above.

Live images of LGR5-eGFP HIOs were obtained using a Lightsheet Z.1

fluorescence microscope (Zeiss).

Creation of adult HIEs
Surgically resected normal colon tissue samples from de-identified patients were
obtained from the UConnHealth Tissue Biorepository. The tissues were washed and
stripped of the underlying muscle layers, then chopped into approximately 5mm pieces
and further washed with cold PBS. Next, the tissue fragments were incubated and
rocked in ice-cold 25 mmol/L EDTA buffer for 40 minutes in the cold room. After
removal of the EDTA buffer, tissue fragments were vigorously resuspended in cold PBS
by vortexing to isolate intestinal crypts. 6-8 repetitions of vortexing for 30 seconds were
performed and supernatants were collected each time. Isolated crypts were pelleted,
washed with cold PBS, and centrifuged at 200g for 3 minutes. The crypts were
resuspended in Matrigel and plated. After Matrigel solidified at 37C, adult enteroid
media was overlaid containing DMEM/F12, B27, penicillin/streptomycin (Invitrogen), Nacetylcysteine (1mM; Sigma-Aldrich), gastrin (10nM; Sigma-Aldrich), nicotinamide
(10mM; Sigma-Aldrich), A83-01 (500nM; Sigma-Aldrich), SB202190 (10μM; Sigma-
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Aldrich),EGF (100ng/ml), noggin (100ng/ml), R-spondin1 (500ng/ml). Y-27632 (10μM)
was added for the first 2 days. Media was changed every 2 days.

Immunofluorescent staining
HIOs or HIEs were harvested and Matrigel was removed by incubating with cold cell
recovery solution for 1h before embedding into OCT. OCT sections were cut at 7μm,
fixed with 10%NBF for 15 minutes and permeabilized with 0.5% Triton X-100. Sections
were blocked with 5% BSA for 1h at room temperature followed by incubation with
primary and secondary antibodies listed in Table 3-1. Where indicated, EdU (10 µM)
was added to the media for 48h before harvesting and imaged following the
manufacturer’s protocol (Thermo Scientific).

Cell viability assay in HIOs
Cell number in a well of HIOs was quantified by incubating with resazurin for 4h and
measuring the emission spectra at 590 nm in a PerkinElmerEnSpire 2300 Multilabel
Reader. HIOs were mock-treated or treated with 25 µMO6-BG and the indicated
concentrations of MNNG for 24, 48 or 72 h. The remaining live cells were quantified
using the ApoLive-Glo viability assay according to manufacturer’s instructions
(Promega). The percentage of live cells was normalized to the initial number.

Senescence assays
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Frozen sections of HIOs and HIEs were stained for SA-β gal activity according to the
manufacturer’s protocol (Cell Signaling Technologies). Briefly, sections were fixed at
room temperature for 10 min in fixation solution. Sections were washed in PBS and
incubated in X-gal solution at 37°C overnight. After washing with PBS, sections were
mounted and visualized by light microscopy. For the conditioned medium assay, HIOs
were mock-treated or treated with 25 µMO6-BG and 2μM MNNG for 48h and changed to
fresh medium for another 48h. The conditioned medium was added to primary human
dermal fibroblasts for 48h followed by culturing in normal growth medium (DMEM+
10%FBS) for an additional 48h before performing the SA-β gal assay.

RT-PCR in HIOs
HIOs were harvested by incubation with TrypLE (Invitrogen) for 5 minutes at 37C. RNA
was isolated using the Nucleospin RNA kit according to the manufacturer’s instructions
(Macherey-Nagel). cDNA was synthesized using the Taqman RT kit (Thermo Scientific).
qRT-PCR was performed using primers listed in Table 3-2. Relative quantification was
achieved by normalizing an Actin gene control.

D. RESULTS

Differentiation of wild-type and MSH2 knockout hESCs into HIOs
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To study the MMR-dependent response to DNA alkylation damage in normal human
intestinal cells, we created HIOs through directed differentiation ofH1 hESCs following a
three-step protocol previously described (Hannan et al., 2013; Spence et al., 2011)
(Figure 3-1A). Differentiation into definitive endoderm cells and then hindgut cells was
marked by expression of the transcription factors Sox17and CDX2, respectively(Figure
3-1B).Clusters of hindgut spheroids were placed into a three-dimensional culture in
Matrigel to form HIOs which grew steadily over several weeks (Figure 3-1C). The HIOs
displayed a single-layer of epithelial cells and a surrounding mesenchymal layer as
described previously (Spence et al., 2011) (Figure 3-1D). The HIOs expressed multiple
intestinal makers including CDX2, E-cadherin and markers of differentiated intestine
such as mucin and villin (Figure 3-1E). The major MMR proteins were expressed in
HIOs though at reduced levels compared to H1 hESCs where they are highly expressed
(Lin et al., 2014) (Figure 3-2A). Two week-old HIOs expressed the MMR proteins MSH2
and MLH1 in the majority of cells coinciding with a high number of proliferating cells as
determined by incorporation of the thymidine analog Ethynyl-2’-deoxyuridine (EdU)
(Figure 3-2B). To determine the effects of MMR loss on intestinal cells, we knocked out
the MSH2 gene in hESCs using the Clustered Regularly Interspaced Short Palindromic
Repeats (CRISPR)-Cas9 gene editing system (Figure 3-2C and 3-2D) prior to
differentiation into HIOs. Knockout of both alleles of MSH2 led to complete loss of
MSH2 protein expression in hESCs (Figure 3-2E) and in subsequent HIOs (Figure 3-2F).
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Figure 3-1.
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Figure 3-1. Generation of HIOs from hESCs.
(A) Schematic of the protocol to differentiate hESCs into HIOs
(B) Immunofluorescent staining of markers for differentiated endoderm (DE) and hindgut
cells.
(C) Bright field images of HIOs embedded in Matrigel at various time points.
(D) Hematoxylin and eosin staining of a section from a 5 week old HIO.
(E) Immunofluorescent staining displaying the expression of the intestinal transcription
factor CDX2, the epithelial cell maker E-cadherin or the intestinal differentiation markers
villin and mucin in HIOs.
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Figure 3-2. MSH2 expression and knockout in HIOs
(A) Western blot analysis of the major MMR proteins in hESCs, hindgut cells and HIOs.
(B) Immunofluorescent (IF) staining of 2 week old HIOs for MSH2 and MLH1 and EdU
incorporation to identify dividing cells.
(C) SfcI digestion of exon 1 of MSH2 PCR products from H1 hESCs or individually
targeted clones. Successful targeting results in ablation of the SfcI site in either a
homozygous (clones 1-3, 5) or heterozygous (clone 4) fashion. (MSH2 KO hESCs were
generated by Dr. Abhijit Rath)
(D) Sequences of H1 hESCs and three homozygous MSH2 KO clones.
(E) Western blot analysis of MSH2 and MLH1 protein expression in wild-type (WT) and
MSH2 knockout (KO) hESCs.
(F) IF staining of MSH2 in WT and MSH2 KO HIOs.
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Alkylation damage leads to both MMR-dependent apoptosis and senescence
We tested the response of intestinal cells to DNA alkylation damage by treating wildtype or MSH2 knockout (KO) HIOs with the SN1 alkylating agent N-methyl-N’-nitro-Nnitrosoguanidine (MNNG). Treatment of MMR-proficient cancer cell lines with MNNG
results in a permanent G2 arrest due to the creation of O6-methylguanine (O6-MeG)
lesions(Li et al., 2016; Stojic et al., 2004). HIOs were pre-treated with the MGMT
inhibitor O6-benzylguanine (O6-BG) to inhibit direct repair of O6-MeG lesions prior to
addition of MNNG, and overall cell survival was monitored. Whereas hESCs show
extensive cell death following 24hours of treatment (Figure 3-S1), wild-type HIOs were
much less sensitive to MNNG even at higher concentrations with longer exposure times
(Figure 3-3A). To determine if any cells were undergoing apoptosis, we performed
immunofluorescence experiments on frozen sections from mock or MNNG-treated HIOs
using an antibody against cleaved-Caspase-3. We found an increase in cleavedCaspase-3-positive cells in wild-type, but not in the MSH2 KO HIOs after MNNG
treatment (Figure 3-3B). Our results indicate that MNNG treatment induces a MMRdependent apoptotic response in intestinal cells within HIOs, but to a much lesser extent
then in undifferentiated hESCs.

When examining proliferation in 2 week old HIOs, we noticed a dramatic reduction of
EdU incorporation in wild-type HIOs treated with MNNG compared to mock-treated
controls (Figure 3-3C and 3-3D). This reduction was not seen in MSH2 KO HIOs
indicative of a MMR-dependent effect. In 5 week old HIOs, the overall amount of
proliferation was reduced consistent with increased differentiation, yet treatment with
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MNNG still yielded a further decline in proliferating cells (Figure 3-3D).Loss of
proliferative capacity in the absence of extensive apoptosis led us to ask whether cells
were senescing in response to MNNG. We found increased numbers of cells that were
positive for senescence-associated β-galactosidase (SA-β gal)activity following48 hours
of MNNG treatment. This SA-β gal activity was not seen in MSH2 KO HIOs (Figure 33E). We observed senescent cells still present in the HIOs one week following treatment
(Figure 3-3F) which suggests that in the absence of immunological clearing, the
senescent cells persist and likely contribute to the unexpectedly high number of
surviving cells following MNNG treatment seen in Figure 3-3A. As a MMR-dependent
senescence response to damage had not been reported before, we checked whether
senescence could be observed in MNNG treated HeLa cervical cancer cells or hESCs.
We did not see any evidence of SA-β gal activity in either HeLa cells or H1 hESCs after
MNNG treatment (Figure 3-3G).
A striking feature of senescent cells is a senescence-associated secretory phenotype
(SASP) which involves the upregulation of matrix-degrading enzymes, cytokines and
growth factors that when secreted can affect neighboring cells (Campisi and d'Adda di
Fagagna, 2007). Using RT-PCR, we observed a subtle, but significant increase in the
mRNA levels of SASP factors such as IL-6 and MMP3 in HIOs following MNNG
treatment (Figure 3-3H). While the increase in expression levels is not dramatic, we
attribute that to the fact that while cDNA is prepared from entire HIOs, only a small
subset of the cells is actively senescing. To further test whether SASP is occurring in
the treated HIOs, we took advantage of the fact that SASP can induce senescence in
other cells in a paracrine fashion (Acosta et al., 2013). We found that conditioned
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Figure 3-3.
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Figure 3-3. Alkylation damage leads to both a MMR-dependent apoptotic and
senescent response
(A) Plot of cell survival of wild-type HIOs after MNNG treatment for 24, 48 or 72 hours.
Data correspond to the average of three independent experiments ± SEM.
(B) Immunofluorescent (IF) staining of cleaved-caspase 3 in wild-type (WT) and MSH2
knockout (KO) HIOs after mock or 2μM MNNG treatment for 48hours.
(C) IF staining of EdU incorporation in WT and MSH2 KO HIOs after mock or 2μM
MNNG treatment for 48hours.
(D) Quantification of EdU incorporation in 2 week and 5 week old WT and MSH2 KO
HIOs with and without MNNG treatment. Statistical significance was assessed from
three independent experiments by the two-tailed Student’s t test: *p < 0.05.
(E) Senescence-associated beta-galactosidase (SA-β gal) staining of WT and MSH2
KO HIOs after mock or 2μM MNNG treatment for 48hours.
(F) SA-β gal staining of WT HIOs immediately after or 1 week after a 48 hour treatment
with 2μM MNNG.
(G) SA-β gal staining of HeLa cells and hESCs after mock or 2μM MNNG treatment for
48hours and 24hours, respectively.
(H) RT-PCR of WT HIOs after mock or 2μM MNNG treatment for 48hours. Data
correspond to the average of three independent experiments ± SEM. Statistical
significance was assessed by the two-tailed Student’s t test: *p < 0.05.
(I)SA-βgal staining of primary fibroblasts after a 48 hour incubation with conditioned
medium from WT and MSH2 KO HIOs that were either mock treated or treated with
2μM MNNG for 48 hours.
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medium from MNNG-treated wild-type HIOs, but not from MSH2 KO HIOs, could induce
senescence in primary human dermal fibroblasts (Figure 3-3I). Together, these results
reveal a novel, MMR-dependent senescence response to DNA damage in intestinal
cells.

The MMR-dependent apoptotic response to damage occurs in intestinal stem
cells

We next explored the basis for the differential damage response observed in HIOs. We
hypothesized that it may be dependent on the type of intestinal cell. Based on our
observations that hESCs are prone to apoptosis(Lin et al., 2014), we posited that cells
undergoing apoptosis were ISCs. To identify ISCs, we utilized a LGR5-eGFP reporter
construct derived from a bacterial artificial chromosome (BAC) containing the LGR5 ISC
marker gene (Barker et al., 2007) in which the initiator methionine was replaced with an
eGFP cassette (McCracken et al., 2014).We stably transfected this BAC into hESCs
prior to differentiation into HIOs. We observed widespread Lgr5-GFP expression in early
stage HIOs, that became more isolated into smaller clusters of cells as the HIOs grew
and matured (Figure 3-4A, 3-4B and 3-4C). LGR5-GFP positive cells actively proliferate
as indicated by EdU labeling, though not every EdU labeled cell is GFP-positive
suggesting that EdU labeling identifies both ISCs and the transient amplifying
cells(Figure 3-4B). We then treated LGR5-GFP HIOs with MNNG and used the cleavedCaspase-3 antibody to detect apoptotic cells. We found that the majority of apoptotic
cells either colocalized or were immediately adjacent to a GFP-positive ISC suggesting
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Figure 3-4.
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Figure 3-4. The MMR-dependent apoptotic response to damage occurs primarily
in intestinal stem cells
(A) Light sheet fluorescence microscopy images of LGR5-GFP HIOs indicating the
presence of intestinal stem cells.
(B) Immunofluorescent staining of 2 week old LGR5-GFP HIOs for GFP expression and
EdU incorporation to identify dividing cells.
(C) Immunofluorescent staining of LGR5-GFP HIOs mock or MNNG treated showing
GFP expression and cleaved-Caspase-3 (c-caspase-3) activation. Arrows indicate
GFP+ cells that are co-localizing with cleaved-Caspase-3+ cells and arrowheads
indicate those that are immediately adjacent.
(D) Quantification of co-localized or adjacent GFP andcleaved-Caspase-3 positive cells
in 2 week old LGR5-GFP HIOs treated with MNNG. Data correspond to the average of
three independent experiments ± SEM.
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that the cells undergoing apoptosis are most likely the ISCs or their immediate
descendants (Figure 3-4C and 3-4D).

Adult intestinal enteroids show multiple responses to alkylation damage
While hESC-derived HIOs are a powerful tool for studying intestinal cell biology,
expression profiles suggest these HIOs resemble more fetal-like tissue than adult
intestine (Finkbeiner et al., 2015). We therefore wished to confirm that the novel
damage response we were observing occurred in adult cells using HIOs derived from
adult colon tissue, also referred to as human intestinal enteroids (HIEs). We obtained
adult normal colon tissue from two de-identifed patients, isolated the crypts and
produced HIEs as described previously(Sato et al., 2011). We observed robust
expression of the intestinal markers E-cadherin, mucin and villin (Figure 3-5A). In media
containing exogenous EGF, noggin and R-spondin (ENR),the HIEs displayed limited
proliferation and reduced survival likely due to loss of ISCs. Addition of the GSK3β
inhibitor CHIR99021, which has been shown to promote the survival and proliferation of
ISCs in culture(Wang et al., 2013; Yin et al., 2014),enhanced proliferation of the HIEs.
As the HIEs grew in the presence of CHIR99021, they displayed increased crypt
budding and maintained this morphology even a week after withdrawing the inhibitor
(Figure 3-5B). Consistent with the maintenance of a more progenitor cell-like phenotype,
the HIEs in the presence of the inhibitor failed to display markers of terminal
differentiation (Figure 3-5C, upper row). However, this effect was reversible as
differentiated cell types re-appeared upon removal of the inhibitor from the medium
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(Figure 3-5C, lower row). To determine if the HIEs were capable of mounting a
senescence response to alkylation damage, we treated HIEs grown in the standard
ENR media or in the presence of the GSK3β inhibitor or in the presence of the inhibitor
for 7 days followed by removal for 2 days with MNNG and examined SA-β gal activity.
Interestingly, the MNNG-treated HIEs in the presence of the GSK3β inhibitor did not
have any senescent cells after treatment (Figure 3-5D, middle column).However, HIEs
that were never treated with the GSK3β inhibitor or in which the inhibitor was withdrawn
both displayed senescent cells following MNNG treatment (Figure 3-5D, left and right
columns). We next measured apoptosis in HIEs following MNNG treatment in the
presence of the GSK3β inhibitor or after withdrawal. We detected apoptotic cells only in
the presence of the inhibitor (Figure 3-5E). Taken together, these results are consistent
with an apoptotic response occurring primarily in ISCs following DNA damage whereas
more differentiated cells likely senesce. In addition to apoptosis, we noticed that MNNG
treatment resulted in the appearance of terminally differentiated cells in HIEs grown with
the GSK3β inhibitor, indicating that in adult tissues, a third response to alkylation
damage is induced differentiation (Figure 3-5F).
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Figure 3-5.
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Figure 3-5. Adult human intestinal enteroids display both apoptotic and
senescent responses to alkylation damage.
(A) Immunofluorescent (IF) staining of adult human intestinal enteroids (HIEs) showing
expression of the epithelial cell marker E-cadherin or the differentiated intestinal cell
markers villin and mucin.
(B) Bright field images of 5 day old adult HIEs in the absence (-) or presence (on) of
GSK3β inhibitor CHIR99021 or following its removal for 4 days (off).
(C) IF staining of mucin and villin in HIEs in the presence of the GSK3β inhibitor (on) or
4 days following its removal (off).
(D) Senescence-associated beta-galactosidase staining of HIEs in the absence (-),
presence (on) or 4 days following the removal of (off) the GSK3β inhibitor after mock or
MNNG treatment for 48hours.
(E) IF staining of cleaved-Caspase-3 (c-Casp-3) in HIEs in the presence of the GSK3β
inhibitor (on) or 4 days following its removal (off) and after mock or MNNG treatment for
48hours.
(F) IF staining for mucin and EdU incorporation in HIEs in the presence of the GSK3β
inhibitor after mock or MNNG treatment.

78

Figure 3-S1

Figure 3-S1. Cell survival of hESCs after MNNG treatment.
Plot of cell survival of wild-type hESCs after MNNG treatment at different concentrations
for 24 hours. Data correspond to the average of three independent experiments ± SEM.
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Table 3-1. Antibodies used for immunofluorescence staining

REAGENT or
RESOURCE
Antibodies
Anti- cleavedcaspase-3
Anti- MSH2
Anti-MLH1
Anti-GFP
Anti-E-cadherin
Anti-mucin
Anti-villin
Anti-Sox17
Anti-CDX2
Alexa Fluor 488
Alexa Fluor 594
Alexa Fluor 555

SOURCE

IDENTIFIER

DILUTION

BD Biosciences

Cat No. 559565

1:100

BD Biosciences
BD Biosciences
Abcam
BD Biosciences
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Abcam
Abcam
Molecular Probes
Molecular Probes
Thermo Scientific

Cat No. 556349
Cat No. 554073
Cat No. ab13970
Cat No. 610181
Cat No. sc-15334

1:100
1:100
1:100
1:100
1:200

Cat No. sc-58897

1:200

Cat No. ab84990
Cat No. ab76541
Cat No. A11034
Cat No. A11032
Cat No. A-21437

1:100
1:100
1:200
1:200
1:200

80

Table 3-2. RT-PCR primers

Gene
Actin
IL-6

IL-1a

Forward (5' to 3')
AGA GCT ACG AGC TGC CTG AC
TGA AAA AGA TGG ATG CTT
CCA AT
GCA GAG CAC ACA AGC TTC
TAG G
TGA AAT AGT TCT TAG TGC CG

MMP3
mTOR

ATA TCA TCT TGA GAC AGG CG
AGC CTC CAG TTC AGC AAG G

IGF1
COX2
CXCL1
p16

ACA AAC ACT TCC TTC CCT TC
TTG TAG CCA TAG TCA GCA TTG
GCC ACA CTC AAG AAT GGG C
ATG GAG CCT TCG GCT GAC T

IL-8
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Reverse (5' to 3')
AGC ACT GTG TTG GCG TAC AG
TAC TCA TCT GCA CAG CTC T
CAA GAG AGC CAC GGC CA
TTC TAA GAA TCT CAA AAA CTC
AAT TG
TTG ATG ATGATG AAC AAT GGA C
ATG GCA ACT ACA GAA TCA CAT
GCC
ACT GAG GAC CTC GGA AT
AAT TAT TTC TGA AAC CCA CTC C
TCC TCC CTT CTG GTC AGT TG
GTA ACT ATT CGG TGC GTT GGG

E. DISCUSSION

Collectively, our data suggest multiple MMR-dependent responses to DNA damage in
different intestinal cell types in human HIOs and HIEs including a novel senescence
response. ISCs appear more prone to undergo apoptosis in response to DNA damage;
whereas, more differentiated cells such as the transient amplifying cells likely senesce.
Both mechanisms may play an important role in tumor suppression in a cellautonomous fashion by eliminating or halting progression of damaged cells themselves.
However, senescence can play an important role in tumor suppression in nonautonomous ways as well. Through SASP activation, senescent cells can have effects
on neighboring cells in vivo. The generation of an inflammatory response that can clear
both the senescent cell but also neighboring malignant and pre-malignant cells may
reduce tumorigenesis (Kang et al., 2011; Xue et al., 2007). In addition, SASP can
induce senescence in other cells as we observed in Figure 3-3I which may spread this
protective effect throughout a field of pre-malignant cells (Acosta et al., 2013).
However, senescence may be an imperfect tumor suppressing mechanism since it can
promote tumorigenesis in some cases. SASP factors have been shown to promote
proliferation of preneoplastic epithelial cells (Bavik et al., 2006; Krtolica et al., 2001) as
well as stimulate angiogenesis and tumor invasion (Coppé et al., 2006). Thus, while
cellular senescence may play an initial role in preventing tumorigenesis, a rapid clearing
of senescent cells from the intestine may be desirable. In vivo, the differentiated
epithelial cells turnover rapidly, which may be sufficient to clear the crypt of cells
undergoing MMR-induced senescence and reduce the negative consequences of SASP.
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On the other hand, long-lasting ISCs undergo apoptosis to immediately eliminate these
cells from the body. The choice between apoptosis and senescence may also relate to
the levels of DNA damage that can be tolerated by a cell. ISCs may be particularly
sensitive to DNA damage, similar to hESCs which undergo rapid apoptosis upon
treatment with MNNG (Lin et al., 2014). hESCs are sensitive to DNA damage due to
enhanced mitochondrial priming(Liu et al., 2013). This hair-trigger apoptosis mechanism
may exist in adult stem cells as well.
The existence of potent MMR-dependent damage responses in intestinal cells suggests
that loss of this pathway might provide an immediate selective advantage during the
early stages of tumorigenesis in LS patients. ISCs that have lost the remaining wild-type
allele of an MMR gene would not be as sensitive to the formation of DNA lesions such
as O6-MeG, which have been detected in human colons as a result of N-nitroso
compounds found in the diet or in cigarette smoke as well as through endogenous
bacterial catalysis and nitrosation of amino acids (Povey et al., 2000). The loss of this
damage response may tilt the balance in what is normally considered to be a neutral
competition between ISCs for residence in the stem cell niche (Lopez-Garcia et al.,
2010; Snippert et al., 2010). This would lead to a colonic crypt heavily populated by
MMR-defective cells that also harbor a mutator phenotype further accelerating the
tumorigenic process. By improving our understanding of the relationship between
environmental factors and specific genetic alterations driving tumorigenesis such as
loss of MMR, we may gain new insights that will help reduce cancer risk in these
patients.
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CHAPTER 4
Conclusions and future directions
The DNA MMR pathway maintains genomic stability through the repair of DNA
replication errors. Germline mutations in MMR genes lead to the cancer predisposition
disease Lynch syndrome. The MMR system is multifaceted. Besides the repair function,
MMR can also induce a DNA damage response such as cell cycle arrest and apoptosis
to certain forms of DNA damage such as alkylation damage. This MMR-dependent DNA
damage response may play an important role in preventing tumorigenesis as well as a
response to some chemotherapies in MMR-proficient tumors. Our overall objective was
to expand upon our observations of this response in some cancer cell lines and
examine the MMR-dependent DNA damage response to alkylation damage in a
nontransformed cell model including hPSCs and HIOs which are the most relevant to
LS.

A. MMR- dependent DNA damage response in hPSCs

From previous studies using MMR proficient and deficient cancer cell lines, we know
that the alkylation agent MNNG induces a MMR-dependent permanent G2 arrest in
cancer cells, with cells only arresting in the second cell cycle after MNNG treatment.
Interestingly, we saw a very different response in hPSCs treated with MNNG. First,
there was massive apoptosis in hPSCs after MNNG treatment without cell cycle arrest
suggesting hPSCs are very sensitive to alkylation damage. This apoptotic response was
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shown to be a MMR-dependent response. It is not surprising that hPSCs employ
extensive mechanisms including MMR to deal with DNA damage to make sure there is
a low tolerance of any damage or mutations accumulated which could be detrimental to
development. Besides alkylation damage, hPSCs are also very sensitive to other DNA
damaging agents such as gamma-irradiation, UV irradiation and etoposide (Grandela,
2007; Momcilovic et al., 2010; Luo et al., 2012), and prone to apoptosis due to
enhanced mitochondrial priming (Liu et al., 2013). This seems to be a unique property
of hPSCs and may be the common downstream effect of various forms of DNA damage.

Second, the timing of the response is also very different. Surprisingly, the apoptosis in
hPSCs was triggered by MNNG treatment in the first S-phase, contrary to the well characterized G2 arrest in the second cell cycle after treatment in the cancer cells,
indicating that the MMR-dependent response to alkylation damage in hPSCs is
fundamentally different than in transformed cells. Based on the futile cycle model, MMR
processing of

Me

G–T mismatches in the first S phase results in persistent unreplicated

single strand gaps that are converted to lethal double strand breaks (DSBs) in the
second S phase. It is the DSBs generated in the second S phase that leads to G2/M
arrest and, eventually, cell death in cancer cells. Thus, transformed cells must have
mechanisms to cope with the unreplicated single strand gaps generated in the first Sphase by MMR processing in order to progress into the second cell cycle. These
mechanisms have been poorly understood. Evidence has shown that 53BP1 foci may
mark unresolved or broken unreplicated single strand gaps that are shielded for repair
in the subsequent G1 or S-phase of the cell cycle using a process that involves the BLM
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helicase for resolution (Mankouri, 2013).However, unlike somatic cells, hPSCs do not
seem to be able to tolerate perturbed S-phase progression likely caused by MMR
processing of the

Me

G–T lesions, leading to immediate apoptosis. It will require further

investigation to determine why hPSCs fail to stabilize and finish the first S-phase similar
to cancer cells. It will be interesting to test whether pathways including 53BP1 and BLM
are activated in hPSCs to cope with the unreplicated single strand gaps, whether other
more lethal lesions such as DSBs are generated in the first S phase to cause apoptosis,
whether the replication stress is so overwhelming that replication forks are collapsing
beyond repair. Co-localization assays of BrdU labeled single strand DNA gaps with
potential proteins involved in the process may be helpful. Single molecule DNA tracing
experiments may be able to help visualize DSBs and collapsed fork structures.

One possible reason that hPSCs might not be able to stabilize the replication in the first
S-phase is that hPSCs lack intra-S phase checkpoints that respond to replication stress
which would normally function to stabilize replication forks and allow for replication restart. Indeed, we found that PSCs failed to activate Chk1 in response to MNNG, thus
missing a possibly important signaling pathway by which cancer cells survive in the first
S-phase. It will be interesting to further investigate why Chk1 is not activated in hPSCs
after MNNG treatment even though the upstream kinases ATM/ATR were found be to
activated in hPSCs in response to MNNG.

Alternatively, MMR proteins may be functioning through a direct signaling mechanism to
recruit stress response proteins to the sites of damage which does not require rounds of
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lesion processing to trigger apoptosis. We have shown that MNNG results in the
phosphorylation of ATM and ATR as well as the MMR-dependent stabilization and
activation of p53, which leads to cell death during the first S phase in hPSCs. Because
the balance of pro- and anti-apoptotic proteins in hPSCs due to enhanced mitochondria
readiness is such that they are more prone to undergo apoptosis compared to
differentiated cells, a low threshold of p53 level is needed to trigger apoptosis in hPSCs.
However, the direct signaling and futile cycle mechanisms may not be exclusive and
may even contribute simultaneously to trigger rapid apoptosis in hPSCs after MNNG
treatment.

B. MMR- dependent DNA damage response in HIOs

The completely different MMR- dependent DNA damage response to MNNG treatment
in hPSCs compared to the established response found in cancer cell lines is very
interesting, and may be partly cell specific to the hPSCs. To expand on this study, we
want to know what the response to alkylation damage is in human intestinal cells and
how that may be implicated in Lynch syndrome tumorigenesis. Thus, we used both
hESCs-derived and patient-derived HIOs, and found that intestinal cells undergo not
only apoptosis, but also a novel senescence response and accelerated differentiation in
a MMR-dependent manner following alkylation damage. All these mechanisms can
have tumor suppression effects by either eliminating or stopping the proliferation of
damaged cells. Thus, loss of MMR function in the intestinal crypts may provide a
selective survival advantage that contributes to tumorigenesis particularly in the context
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of increased DNA damage. The environment in the colon with N-nitroso carcinogens
from diet and bacterial metabolism may contribute to a selective pressure on the cells.

We also found that the cells undergoing apoptosis are primarily the intestinal stem cells
suggesting different cell types in the intestine have different responses to damage. The
choice between an apoptotic or senescent response may relate to the levels of DNA
damage that can be tolerated by a cell. However, the mechanisms of how cells make
those choices remain largely unknown because many of the same signaling pathways
(such as ATM, ATR, p53 etc) are activated due to DNA damage, yet resulting in
different outcomes in the end. It would be very interesting to understand where the
divergence is and what controls the pathway choice. There might be cell type specific
regulations of the signaling pathways. ISCs may be particularly sensitive to DNA
damage, similar to hESCs which undergo rapid apoptosis upon treatment with MNNG.
The mitochondria priming mechanism that makes hESCs prone to apoptosis may also
exist in ISCs.

All the cells in Lynch syndrome patients are heterozygous in one of the MMR genes and
they have intact MMR functions, until one cell loses the other wild type allele and
becomes MMR deficient at some point in the patient’s lifetime. Those MMR deficient
cells could potentially become cancer cells. Thus, it could be a preventive strategy if a
potential compound can be found to selectively kill MMR deficient normal
(noncancerous) cells and spare the surrounding majority of MMR proficient cells in
young LS patients before they actually develop any tumor. Killing MMR deficient normal
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cells might be easier to achieve and pose less harm to the rest of the body than killing
MMR deficient cancer cells after a tumor has developed in LS patients. For this strategy,
HIOs can serve as a great model to screen selective killing compounds on normal
human intestinal tissue by comparing WT and MMR deficient HIOs. In addition, HIOs
containing specific MMR gene mutations can be used to study how a specific mutation
can affect MMR function including the DNA damage response in the intestinal cells
providing a functional screen that is more physiologically relevant to LS than functional
studies in vitro or in two-dimensional cancer cell lines.

In summary, this study has investigated the MMR-dependent DNA damage response to
alkylation damage in hPSCs and HIOs. The response may lead to different outcomes in
different cell types and the mechanisms may also vary, but overall the MMR-dependent
DNA damage response likely has a tumor suppression effect. Our results raise the
possibility that loss of MMR in LS may lead to loss of this protective mechanism in early
stage of tumorigenesis and allow MMR deficient cells to have a survival advantage
while accumulating mutations that ultimately result in cancer (Figure 4-1).
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Figure 4-1.
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Figure 4-1. MMR deficient ISCs gain survival advantage to populate crypts.
Normally, ISCs at the bottom of a crypt proliferate and compete for the stem cell niche.
One of the ISCs will win and occupy the niche, then its descendants will further populate
the whole crypt. This process is random, each ISC has the equal chance to win (upper).
However, when one of the ISCs loses MMR, the balance is shifted. When encountering
certain DNA damage, the MMR proficient ISCs will have a MMR-dependent DNA
damage response leading to apoptosis, while MMR deficient ISC can survive to take
over the niche and populate the crypt (lower). Now the MMR deficient ISCs will always
have better chance to populate the crypts and those crypts are potentially in danger of
becoming cancer.
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